Polivy (polatuzumab vedotin-piiq) – To treat adult patients with relapsed or refractory diffuse large B-cell lymphoma
POLIVY DOSAGE AND ADMINISTRATION
• The recommended dose of POLIVY is 1.8 mg/kg as an intravenous infusion over 90 minutes every 21 days for 6 cycles in combination with
bendamustine and a rituximab product. Subsequent infusions may be administered over 30 minutes if the previous infusion is tolerated.
• Premedicate with an antihistamine and antipyretic before POLIVY.
POLIVY INDICATIONS AND USAGE
POLIVY is a CD79b-directed antibody–drug conjugate indicated in combination with bendamustine and a rituximab product for the treatment of
adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, after at least two prior therapies.
Accelerated approval was granted for this indication based on complete response rate. Continued approval for this indication may be contingent
upon verification and description of clinical benefit in a confirmatory trial.
POLIVY DRUG INTERACTIONS
Concomitant use of strong CYP3A inhibitors or inducers has the potential to affect the exposure to unconjugated monomethyl auristatin E (MMAE).
POLIVY DOSAGE FORMS AND STRENGTHS
For injection: 140 mg of polatuzumab vedotin-piiq as a lyophilized powder in a single-dose vial.
POLIVY USE IN SPECIFIC POPULATIONS
• Hepatic impairment has the potential to increase exposure to MMAE. Monitor patients for adverse reactions.
• Lactation: Advise not to breastfeed.